Navigation Links
ViroPharma to Host Investor 'Teach-In' Educational Symposium on Hereditary Angioedema

- Hereditary Angioedema (HAE) and the Dawn of New Therapeutics -

EXTON, Pa., March 4 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today that the company will provide a live audio webcast of its 'Teach-in' educational event for investors on Hereditary Angioedema (HAE), on Tuesday, March 10, 2009. Lectures will be provided by Anthony J. Castaldo and Janet Long, president and vice president, respectively, of the U.S. Hereditary Angioedema Association (HAEA), and Aleena Banerji, M.D., an HAE specialist at Massachusetts General Hospital.

The 'Teach-in', entitled 'Hereditary Angioedema (HAE) and The Dawn of New Therapeutics' will be held from 5:00 P.M. until 6:30 P.M. Eastern Time on Tuesday March 10, 2009.

"We are thrilled to enlist the participation of these key opinion leaders in the field of hereditary angioedema, who each day deal with the severe ramifications of HAE in their patients, families, and constituents," commented Will Roberts, ViroPharma's vice president of corporate communications. "As the proud stewards of the only approved C1 inhibitor therapy on the market, ViroPharma is committed to fostering our role as leaders in the space through the execution of essential disease awareness and investor programs."

A live audio webcast of the meeting may be accessed via the investor section of the ViroPharma corporate website, The archive of the meeting will be available through March 24, 2009.

About Cinryze C1 Inhibitor (human)

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. C1 inhibitor therapy has been used acutely for more than 30 years in Europe to treat patients with C1 inhibitor deficiency. Cinryze has not been approved for acute treatment in the United States or any other jurisdiction.

Cinryze has been well tolerated. The most common adverse reactions observed have been upper respiratory infection, sinusitis, rash and headache. No drug-related serious adverse events (SAEs) have been observed in clinical trials. Severe hypersensitivity reactions may occur. Thrombotic events have occurred in patients receiving high dose off-label C1 inhibitor therapy well above the approved treatment dosage regimen. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening patients for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.

Cinryze is for intravenous use only. A dose of 1000 Units Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, The company encourages investors to consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
2. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
3. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. ViroPharma Provides Update on Vancocin(R)
5. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
6. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
7. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
8. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
9. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... --  Divoti USA will engrave and process all ... the latest FDA requirements, which stipulates new criteria regarding medical device ... of Medical ID jewelry such as Medical ID Bracelets, can rest ... terms of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving ...
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ... Aspen Surgical facility in Las Piedras, Puerto ... scalpels and blades. ... that the facility sustained minor structural damage, temporary loss ... Maria. Repairs have been completed, manufacturing operations have resumed, ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
Breaking Medicine Technology: